Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will look for the highest tolerated dose of dalotuzumab (MK-0646) given as weekly,
every other week. or a every three week infusion.
The hypothesis of this study is that administration of dalotuzumab as a one- to two-hour
weekly, every other week, or every three week infusion in participants with advanced cancer
will be generally safe and tolerated at a dose which achieves a trough concentration ≥3
μg/mL.